Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1995, and the nine-month period ended on the same date for Repligen Corporation. The company is a biotechnology firm focused on research and development, currently undergoing significant restructuring to divest manufacturing operations and reduce overhead. Management has indicated that without additional financing or successful restructuring, the company may be forced to curtail operations or seek bankruptcy protection by September 30, 1996.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1995 | Nine Months Ended Dec 31, 1995 |
|---|---|---|
| Total Revenues | $2,104,366 | $9,959,800 |
| Net Loss | ($2,302,025) | ($5,874,865) |
| Net Loss Per Share | ($0.15) | ($0.38) |
| Cash and Cash Equivalents | $8,710,617 | $8,710,617 (Ending Balance) |
| Working Capital | $4,414,303 | $4,414,303 (Ending Balance) |
| Net Cash Used in Operating Activities | N/A | ($4,958,676) |
Debt and Liquidity: The company has no term loans payable as of December 31, 1995, having paid off a $4.62 million loan during the period. However, the company is in default on three equipment leases with an aggregate claim of approximately $3.7 million (including penalties and interest). Total current liabilities stand at $7,986,125.
Material Changes Versus Prior Period
- Revenue Decline: Total revenues decreased 41% for the three months and 16% for the nine months compared to the prior year. This was driven by the termination of the Eli Lilly collaboration (CD11b Program) in October 1995 and reduced funding from Repligen Clinical Partners, L.P.
- Expense Reduction: Total expenses dropped significantly (53% for the quarter, 48% for the nine months) due to major restructuring efforts in fiscal 1995, including workforce reductions and facility subleases.
- Restructuring Charges: While the current quarter had no new restructuring charges, the nine-month period included a $11.3 million charge in fiscal 1995 (mostly in Q4) covering severance, lease losses, and asset write-offs.
- Liquidity Position: Cash and cash equivalents decreased by approximately $5.1 million during the nine-month period, reflecting net operating losses and capital expenditures.
Outlook, Risks, and Management Commentary
- Restructuring Strategy: Repligen is executing a letter of intent to sell its "Allegro Biologics" division to Genzyme Corporation. This transaction is contingent on resolving disputes with equipment lessors.
- Liquidity Risk: Management estimates funds will last through September 30, 1996, absent additional financing. If the Genzyme transaction fails or creditor disputes are not resolved, the company may cease operations or seek bankruptcy protection.
- Partnership Funding: Repligen Clinical Partners, L.P., which funds the rPF4 program, has working capital expected to be exhausted by March or April 1996. The company does not anticipate further revenue from this partnership after the fourth quarter of fiscal 1996.
- Legal Contingencies: The company is in default on equipment leases. Lessors have accelerated future payments, claiming approximately $3.7 million. Negotiations for early termination and debt reduction are ongoing.
Investor Verification Checklist
- Verify the status of the asset purchase agreement with Genzyme Corporation and the conditions required for closing.
- Confirm the outcome of negotiations with equipment lessors regarding the $3.7 million in accelerated lease claims.
- Assess the likelihood of securing additional equity financing or third-party funding before September 1996.
- Review the financial status of Repligen Clinical Partners, L.P., and the probability of the rPF4 program termination.
- Monitor the company's cash burn rate against the projected runway to September 30, 1996.